Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 29, 2021 10:00 ET | Source: Longeveron

Longeveron Announces Potential Biomarker Correlating with Lomecel-B Bioactivity

Lomecel-B significantly decreased biomarker Tie-2 in Aging Frailty subjects at 270 days compared to placeboSignificant, dose-dependent decrease in Tie-2 at Day 270Oral presentation today at the...
September 28, 2021 08:00 ET | Source: Longeveron

Longeveron Announces Multiple Presentations at the 11th Annual International Conference on Frailty & Sarcopenia Research

MIAMI, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related,...
September 21, 2021 08:00 ET | Source: Longeveron

Longeveron Announces Dr. Jorge Ruiz as Speaker for Roundtable Discussion & Presentation at 2021 International Conference for Frailty & Sarcopenia Research

-- Jorge Ruiz, M.D., Associate Director for Clinical Affairs, Geriatric Research at the Miami VA Healthcare System, will present Longeveron’s Aging Frailty Phase 2b Trial Data -- National...
September 13, 2021 09:19 ET | Source: Longeveron

Longeveron Partners with Kinesiometrics to Create and Implement Cutting-Edge Smart Phone App to Measure Physical Responses to Cell Therapy

MIAMI, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing its proprietary product, Lomecel-B, and other...
September 09, 2021 08:00 ET | Source: Longeveron

Longeveron Announces Final Results of Phase 1 Clinical Study of Lomecel-B Injection in Hypoplastic Left Heart Syndrome Patients

--Study meets primary safety endpoint: no major adverse cardiac events (MACE), nor any treatment-related infections during the first month post-treatment. --Secondary endpoints measured per protocol...
September 01, 2021 08:00 ET | Source: Longeveron

Longeveron to Present at H.C. Wainwright 23rd Annual Global Investor Conference

MIAMI, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related...
August 13, 2021 07:00 ET | Source: Longeveron

Longeveron Announces Topline Results of Phase 2b Study of Lomecel-B for Aging Frailty

-- Study meets one of the two analyses of primary efficacy endpoint: statistically significant dose-response in six-minute walk test (6MWT) at Day 180 -- Longeveron to hold conference call today at...
August 13, 2021 07:00 ET | Source: Longeveron

Longeveron Inc. Provides Corporate Update and Reports Second Quarter 2021 Financial Results

MIAMI, Aug. 13, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related...
August 10, 2021 08:30 ET | Source: Longeveron

Longeveron to Release Second Quarter 2021 Financial Results and Hold Conference Call on August 13, 2021

MIAMI, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related...
July 06, 2021 08:00 ET | Source: Longeveron

Longeveron Announces First Patient Treated in Phase 2b Hypoplastic Left Heart Syndrome (HLHS) Clinical Study

• Multicenter, double-blinded, controlled study designed to evaluate safety & efficacy of Lomecel-B intramyocardial injection in infants with HLHS • Funded by the National Heart, Lung and...